Rastetter increased his holding by 100% to a total of $2.00. In addition to Rastetter, 2 other RGLS executives reported Buy trades in the last month.
Based on Regulus` latest earnings report from March 31, the company posted quarterly revenue of $4.2M and GAAP net loss of $14.49M. In comparison, last year the company earned revenue of $736k and had a GAAP net loss of $11.97M. The company has a one year high of $25.60 and a one year low of $6.13. Currently, Regulus has an average volume of 524.4k.
Based on 5 analyst ratings, the analyst consensus is Strong Buy with an average price target of $31.80, reflecting a -67.9% downside. RGLS got 29 Buy ratings in a row, starting November 2012. 7 different firms, including BMO Capital and Cowen & Co., currently also have a Buy rating on the stock.
Looking at blogger coverage of RGLS, there is a 75% Bullish tendency on the stock, in relation to a 67% average bullish tendency within the Healthcare sector.
In the last 30 days, insiders have sold $3.78M worth of RGLS shares and purchased $1.02M worth of RGLS shares. Over the last 3 months, the insider sentiment on Regulus has been neutral based on 61 corporate insider transactions. This sentiment is higher than the average sector sentiment of insiders.
Regulus Therapeutics Inc is a biopharmaceutical company. The Company is engaged in discovering and developing drugs that target micro RNAs to treat various diseases.